Literature DB >> 19249243

Effect of pyrazinamidase activity on pyrazinamide resistance in Mycobacterium tuberculosis.

Patricia Sheen1, Patricia Ferrer, Robert H Gilman, Jon López-Llano, Patricia Fuentes, Eddy Valencia, Mirko J Zimic.   

Abstract

Resistance of Mycobacterium tuberculosis to pyrazinamide is associated with mutations in the pncA gene, which codes for pyrazinamidase. The association between the enzymatic activity of mutated pyrazinamidases and the level of pyrazinamide resistance remains poorly understood. Twelve M. tuberculosis clinical isolates resistant to pyrazinamide were selected based on Wayne activity and localization of pyrazinamidase mutation. Recombinant pyrazinamidases were expressed and tested for their kinetic parameters (activity, k(cat), K(m), and efficiency). Pyrazinamide resistance level was measured by Bactec-460TB and 7H9 culture. The linear correlation between the resistance level and the kinetic parameters of the corresponding mutated pyrazinamidase was calculated. The enzymatic activity and efficiency of the mutated pyrazinamidases varied with the site of mutation and ranged widely from low to high levels close to the corresponding of the wild type enzyme. The level of resistance was significantly associated with pyrazinamidase activity and efficiency, but only 27.3% of its statistical variability was explained. Although pyrazinamidase mutations are indeed associated with resistance, the loss of pyrazinamidase activity and efficiency as assessed in the recombinant mutated enzymes is not sufficient to explain a high variability of the level of pyrazinamide resistance, suggesting that complementary mechanisms for pyrazinamide resistance in M. tuberculosis with mutations in pncA are more important than currently thought.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19249243      PMCID: PMC2691962          DOI: 10.1016/j.tube.2009.01.004

Source DB:  PubMed          Journal:  Tuberculosis (Edinb)        ISSN: 1472-9792            Impact factor:   3.131


  29 in total

1.  pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis isolates from northwestern Russia.

Authors:  H J Marttila; M Marjamäki; E Vyshnevskaya; B I Vyshnevskiy; T F Otten; A V Vasilyef; M K Viljanen
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

2.  Relationship between pyrazinamide resistance, loss of pyrazinamidase activity, and mutations in the pncA locus in multidrug-resistant clinical isolates of Mycobacterium tuberculosis.

Authors:  M Mestdagh; P A Fonteyne; L Realini; R Rossau; G Jannes; W Mijs; K A De Smet; F Portaels; E Van den Eeckhout
Journal:  Antimicrob Agents Chemother       Date:  1999-09       Impact factor: 5.191

3.  Global incidence of multidrug-resistant tuberculosis.

Authors:  Matteo Zignol; Mehran S Hosseini; Abigail Wright; Catharina Lambregts-van Weezenbeek; Paul Nunn; Catherine J Watt; Brian G Williams; Christopher Dye
Journal:  J Infect Dis       Date:  2006-07-12       Impact factor: 5.226

4.  pncA mutations as a major mechanism of pyrazinamide resistance in Mycobacterium tuberculosis: spread of a monoresistant strain in Quebec, Canada.

Authors:  S J Cheng; L Thibert; T Sanchez; L Heifets; Y Zhang
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

5.  Sterilising action of pyrazinamide in models of dormant and rifampicin-tolerant Mycobacterium tuberculosis.

Authors:  Y Hu; A R Coates; D A Mitchison
Journal:  Int J Tuberc Lung Dis       Date:  2006-03       Impact factor: 2.373

6.  Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis.

Authors:  A Scorpio; P Lindholm-Levy; L Heifets; R Gilman; S Siddiqi; M Cynamon; Y Zhang
Journal:  Antimicrob Agents Chemother       Date:  1997-03       Impact factor: 5.191

7.  Simultaneous identification and typing of multi-drug-resistant Mycobacterium tuberculosis isolates by analysis of pncA and rpoB.

Authors:  T J Brown; Ö Tansel; G L French
Journal:  J Med Microbiol       Date:  2000-07       Impact factor: 2.472

8.  Study of the structure-activity relationships for the pyrazinamidase (PncA) from Mycobacterium tuberculosis.

Authors:  N Lemaitre; I Callebaut; F Frenois; V Jarlier; W Sougakoff
Journal:  Biochem J       Date:  2001-02-01       Impact factor: 3.857

9.  Characterization of Mycobacterium tuberculosis nicotinamidase/pyrazinamidase.

Authors:  Hua Zhang; Jiao-Yu Deng; Li-Jun Bi; Ya-Feng Zhou; Zhi-Ping Zhang; Cheng-Gang Zhang; Ying Zhang; Xian-En Zhang
Journal:  FEBS J       Date:  2008-01-14       Impact factor: 5.542

10.  Purification, gene cloning, targeted knockout, overexpression, and biochemical characterization of the major pyrazinamidase from Mycobacterium smegmatis.

Authors:  H I Boshoff; V Mizrahi
Journal:  J Bacteriol       Date:  1998-11       Impact factor: 3.490

View more
  36 in total

1.  Pyrazinoic acid efflux rate in Mycobacterium tuberculosis is a better proxy of pyrazinamide resistance.

Authors:  Mirko Zimic; Patricia Fuentes; Robert H Gilman; Andrés H Gutiérrez; Daniela Kirwan; Patricia Sheen
Journal:  Tuberculosis (Edinb)       Date:  2011-10-17       Impact factor: 3.131

2.  Kinetics and inhibition of nicotinamidase from Mycobacterium tuberculosis.

Authors:  Derrick R Seiner; Subray S Hegde; John S Blanchard
Journal:  Biochemistry       Date:  2010-11-09       Impact factor: 3.162

3.  Streptolysin-O/antibiotics adjunct therapy modulates site-specific expression of extracellular matrix and inflammatory genes in lungs of Rhodococcus equi infected foals.

Authors:  Volkan Gurel; Kristyn Lambert; Allen E Page; Alan T Loynachan; Katherine Huges; John F Timoney; Michael Fettinger; David W Horohov; John McMichael
Journal:  Vet Res Commun       Date:  2013-03-09       Impact factor: 2.459

4.  A new approach for pyrazinamide susceptibility testing in Mycobacterium tuberculosis.

Authors:  Mirko Zimic; Sebastian Loli; Robert H Gilman; Andrés Gutierrez; Patricia Fuentes; Milagros Cotrina; Daniela Kirwan; Patricia Sheen
Journal:  Microb Drug Resist       Date:  2012-02-28       Impact factor: 3.431

5.  Pyrazinamide Is a Two-Edged Sword: Do WHO Guidelines Matter?

Authors:  Kwok-Chiu Chang; Wing-Wai Yew; Ying Zhang
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

6.  Density functional and molecular docking studies towards investigating the role of single-wall carbon nanotubes as nanocarrier for loading and delivery of pyrazinamide antitubercular drug onto pncA protein.

Authors:  Nabanita Saikia; Sanchaita Rajkhowa; Ramesh C Deka
Journal:  J Comput Aided Mol Des       Date:  2013-02-15       Impact factor: 3.686

Review 7.  Systematic review of mutations in pyrazinamidase associated with pyrazinamide resistance in Mycobacterium tuberculosis clinical isolates.

Authors:  Sarah M Ramirez-Busby; Faramarz Valafar
Journal:  Antimicrob Agents Chemother       Date:  2015-06-15       Impact factor: 5.191

8.  Peruvian and globally reported amino acid substitutions on the Mycobacterium tuberculosis pyrazinamidase suggest a conserved pattern of mutations associated to pyrazinamide resistance.

Authors:  Mirko Zimic; Patricia Sheen; Miguel Quiliano; Andrés Gutierrez; Robert H Gilman
Journal:  Infect Genet Evol       Date:  2009-12-04       Impact factor: 3.342

9.  pncA gene expression and prediction factors on pyrazinamide resistance in Mycobacterium tuberculosis.

Authors:  Patricia Sheen; Katherine Lozano; Robert H Gilman; Hugo J Valencia; Sebastian Loli; Patricia Fuentes; Louis Grandjean; Mirko Zimic
Journal:  Tuberculosis (Edinb)       Date:  2013-07-16       Impact factor: 3.131

10.  Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis isolates from Korea and analysis of the correlation between the mutations and pyrazinamidase activity.

Authors:  Jee-Hyun Yoon; Ji-Sun Nam; Kyung-Jin Kim; Young-Tae Ro
Journal:  World J Microbiol Biotechnol       Date:  2014-07-18       Impact factor: 3.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.